Open AccessFactors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
Author(s) -
Mathieu Chappuy,
Fadi Meroueh,
Benoît Trojak,
Jérôme Bachellier,
Patrick Bendimerad,
Margaux Kosim,
Peter Hjelmström,
Philippe Nubukpo,
Georges Brousse,
Benjamin Rolland
Publication year - 2021
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s311674
Subject(s) - buprenorphine , medicine , opioid use disorder , prison , confidence interval , psychiatry , odds ratio , logistic regression , demography , opioid , psychology , receptor , criminology , sociology
Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations.